TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23417565

Group type: EXPERIMENTAL
Intervention: FACT-EGFRI-18 questionnaire
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Physical items associated with mcAEs
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Recommendation for additional adverse event items
Number of subjects: 10
Study: 23418134

Group type: EXPERIMENTAL
Intervention: Smart phones
Number of subjects: 203

Group type: COMPARATOR
Intervention: Non-smart phones
Number of subjects: 203
Study: 23418272

Group type: EXPERIMENTAL
Intervention: Pretreatment CMV DNA of <18,200 (4.3 log(10)) IU/mL
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: CMV load suppression <137 IU/mL (<2.1 log(10)) at days 7, 14, and 21
Number of subjects: 267
Study: 23418288

Group type: EXPERIMENTAL
Intervention: Blood-based gene expression score (GES)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Clinical factors and MPI
Number of subjects: 537
Study: 23418734

Group type: EXPERIMENTAL
Intervention: Retinal function imager (RFI)
Number of subjects: 67
Study: 23419735

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 4750

Group type: COMPARATOR
Intervention: No statin therapy (Control)
Number of subjects: 4750
Study: 23422236

Group type: EXPERIMENTAL
Intervention: ADHD Rating Scale (ADHD-RS)
Number of subjects: 892
Study: 23422747

Group type: COMPARATOR
Intervention: IgH translocations in AA patients (40%)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Somatic copy number abnormalities in AA patients
Number of subjects: 115

Group type: COMPARATOR
Intervention: Transcriptional profile associated with high-risk disease in AA patients
Number of subjects: 115
Study: 23423135

Group type: EXPERIMENTAL
Intervention: Continuous interscalene nerve block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 23424023

Group type: EXPERIMENTAL
Intervention: Hybrid-balloon dilation
Number of subjects: 175
Study: 23425164

Group type: EXPERIMENTAL
Intervention: Magnetic device for sphincter augmentation
Number of subjects: 100
Study: 23425215

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: IL-6 (baseline)
Number of subjects: 53
Study: 23425514

Group type: EXPERIMENTAL
Intervention: Continuous peritoneal lavage (PL) using the Velomedix Inc. automated PL system
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cooled saline intravenous infusions and cooled blankets (historical controls)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Continuous peritoneal lavage (PL)
Number of subjects: 16
Study: 23425608

Group type: EXPERIMENTAL
Intervention: Dance intervention twice weekly for eight months in addition to usual school health services
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual school health services alone
Number of subjects: 112
Study: 23425763

Group type: EXPERIMENTAL
Intervention: Urinary proteomics analysis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Urinary biomarkers for sepsis differentiation
Number of subjects: 30
Study: 23426034

Group type: EXPERIMENTAL
Intervention: Highest quartile of homocysteine (>9.85 μmol/L)
Number of subjects: 988

Group type: COMPARATOR
Intervention: Lowest quartile of homocysteine (≤6.74 μmol/L)
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Highest quartile of cysteine (>309 μmol/L)
Number of subjects: 988

Group type: COMPARATOR
Intervention: Lowest quartile of cysteine (≤260 μmol/L)
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Homocysteine association with proximal colon tumors
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Cysteine association with rectal tumors
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Cysteine association with proximal tumors
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Homocysteine and cysteine associations with localized tumors
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Homocysteine and cysteine associations with metastases
Number of subjects: 988
Study: 23426279

Group type: EXPERIMENTAL
Intervention: SAR3419
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: SAR3419 + VXL (vincristine/dexamethasone/l-asparaginase)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: SAR3419 (protracted therapy after VXL)
Number of subjects: 7
Study: 23426337

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 490
Study: 23426943

Group type: EXPERIMENTAL
Intervention: T-Rapa cell infusion at day 14 post-HCT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: T-Rapa cell infusion
Number of subjects: 40
Study: 23427330

Group type: EXPERIMENTAL
Intervention: Conventional Rice (CR)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Higher-Zinc Rice (HZnR)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Conventional Rice plus Zinc Fortificant (CR+Zn)
Number of subjects: 42
Study: 23428306

Group type: EXPERIMENTAL
Intervention: sGP130
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: sIL-6r
Number of subjects: 563

Group type: COMPARATOR
Intervention: MetS
Number of subjects: 563
Study: 23428875

Group type: EXPERIMENTAL
Intervention: PegIFNα-2a 135-180 μg/week plus RBV 200-1200 mg/day for 48 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Matched untreated historical controls (n=31)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: PegIFNα-2a plus RBV
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: EVR
Number of subjects: 32
Study: 23429230

Group type: EXPERIMENTAL
Intervention: Menstruation phase
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Late follicular phase
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mid-luteal phase
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall comparison of phases
Number of subjects: 80
Study: 23429330

Group type: EXPERIMENTAL
Intervention: S80/V60 on days 1, 8, and 15
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: S80/V80 on days 1, 8, and 15
Number of subjects: 27
Study: 23429725

Group type: EXPERIMENTAL
Intervention: 3'-AmNic-rEPA (4-400 μg)
Number of subjects: 11
Study: 23429998

Group type: EXPERIMENTAL
Intervention: Functional class improvement from FC III to FC I/II (n=263)
Number of subjects: 982

Group type: COMPARATOR
Intervention: Functional class unchanged (n=645)
Number of subjects: 982

Group type: COMPARATOR
Intervention: Functional class worsened to FC IV (n=74)
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Overall cohort with functional class improvement
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: CTD cohort with functional class improvement
Number of subjects: 982
Study: 23430175

Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin hydrochloride for 3 days after each monthly IVT injection.
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 178
Study: 23430598

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT), applied twice a week
Number of subjects: 690

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 690
Study: 23430599

Group type: EXPERIMENTAL
Intervention: Integrated cardiac rehabilitation programme including four psychoeducative consultations and 12 weeks of individualised exercise training plus standard medical follow-up.
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard medical follow-up (Control group).
Number of subjects: 210
Study: 23432088

Group type: EXPERIMENTAL
Intervention: ME-FICE plus pCLE
Number of subjects: 60

Group type: COMPARATOR
Intervention: ME-FICE
Number of subjects: 60
Study: 23432512

Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 300

Group type: COMPARATOR
Intervention: Decitabine
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Azacitidine (in patients ≥ 65 years)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Decitabine (in patients ≥ 65 years)
Number of subjects: 300
Study: 23433102

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate (PA)
Number of subjects: 4069

Group type: COMPARATOR
Intervention: Mefloquine + artesunate (MQ + AS)
Number of subjects: 4069

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 4069

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 4069
Study: 23433817

Group type: EXPERIMENTAL
Intervention: Branched or fenestrated endografts
Number of subjects: 650
Study: 23433846

Group type: EXPERIMENTAL
Intervention: AZD8330 (20 mg BID)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: AZD8330 (various doses)
Number of subjects: 82
Study: 23433931

Group type: EXPERIMENTAL
Intervention: LGE-CMR detected fibrosis
Number of subjects: 373
Study: 23434121

Group type: COMPARATOR
Intervention: Moderately obese individuals
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Severely obese individuals
Number of subjects: 463
Study: 23434314

Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: reboxetine
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 107
Study: 23434626

Group type: EXPERIMENTAL
Intervention: Sprint Fidelis leads
Number of subjects: 976

Group type: COMPARATOR
Intervention: Sprint Quattro leads
Number of subjects: 976

Group type: EXPERIMENTAL
Intervention: Combined endpoint of mortality and heart failure hospitalisations
Number of subjects: 976
Study: 23435023

Group type: EXPERIMENTAL
Intervention: Perception of body weight (healthy, underweight, or overweight)
Number of subjects: 689
Study: 23435461

Group type: EXPERIMENTAL
Intervention: Reduced-intensity allogeneic hematopoietic stem cell transplantation (HSCT)
Number of subjects: 90
Study: 23435697

Group type: EXPERIMENTAL
Intervention: Adherence support approaches used in PrEP trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participant-centered approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored strategies beyond education
Number of subjects: 0
Study: 23436052

Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy (RT) and vandetanib (a vascular endothelial growth factor receptor 2 inhibitor)
Number of subjects: 35
Study: 23437092

Group type: EXPERIMENTAL
Intervention: ON SIROLIMUS AFTER 12 MONTHS
Number of subjects: 28

Group type: COMPARATOR
Intervention: OFF SIROLIMUS AFTER 12 MONTHS
Number of subjects: 28
Study: 23439103

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: SYNTAX score II
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Anatomical SYNTAX score
Number of subjects: 1800
Study: 23439262

Group type: EXPERIMENTAL
Intervention: ABT-450/r 150/100 mg once daily and ABT-072 400 mg once daily with weight-based ribavirin 1000-1200 mg/day dosed twice daily for 12 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ABT-450/r and ABT-072 with ribavirin
Number of subjects: 11
Study: 23439261

Group type: EXPERIMENTAL
Intervention: Leptin treatment for 25.8 ± 3.7 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Leptin treatment
Number of subjects: 50
Study: 23440228

Group type: EXPERIMENTAL
Intervention: Depression (n = 187; 32.9%)
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Psychiatric treatment via antidepressant medication (n = 126; 22.2%)
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Psychotherapy (n = 39; 6.9%)
Number of subjects: 568
Study: 23440355

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 0
Study: 23440998

Group type: EXPERIMENTAL
Intervention: Caregivers prior to stem cell transplantation
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Younger caregivers
Number of subjects: 109

Group type: COMPARATOR
Intervention: Male and female caregivers
Number of subjects: 109
Study: 23441892

Group type: EXPERIMENTAL
Intervention: Phlebotomy
Number of subjects: 31
Study: 23442309

Group type: EXPERIMENTAL
Intervention: Image-guided 20-gauge PTCNB
Number of subjects: 151
Study: 23442518

Group type: EXPERIMENTAL
Intervention: Kochujang (KCJ) supplement (32 g/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (32 g/day)
Number of subjects: 60
Study: 23442588

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (PRV) administered in three doses with an interval of 4 to 10 weeks (28 to 70 days)
Number of subjects: 110
Study: 23443063

Group type: EXPERIMENTAL
Intervention: SOPsystem
Number of subjects: 100

Group type: COMPARATOR
Intervention: Food diaries (FDs) without SOPsystem
Number of subjects: 100
Study: 23443507

Group type: EXPERIMENTAL
Intervention: UCN-01 65 mg/m(2) with perifosine 100 mg a day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Perifosine 150 mg every 6 h on day 1 followed by 100 mg once a day continuously in 28-day cycles
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: UCN-01 at three dose levels (DL1=40 mg/m(2); DL2=65 mg/m(2); DL3=90 mg/m(2))
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: UCN-01 and perifosine combination
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: UCN-01 and perifosine
Number of subjects: 13
Study: 23443729

Group type: EXPERIMENTAL
Intervention: Uric Acid (UA) in women
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Uric Acid (UA) in men
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Uric Acid (UA)
Number of subjects: 366
Study: 23443801

Group type: EXPERIMENTAL
Intervention: Temozolomide 150 mg/m(2) administered daily on a seven-day-on, seven-day-off schedule for each 28-day cycle.
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Temozolomide
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Serum methylation assay
Number of subjects: 86
Study: 23444221

Group type: EXPERIMENTAL
Intervention: FOXC1-negative tumors
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: FOXC1 expression
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: FOXC1 copy number loss
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: PBX1 copy number gain
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: FOXC1 protein expression
Number of subjects: 132
Study: 23445216

Group type: EXPERIMENTAL
Intervention: Diabetes group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 23445875

Group type: EXPERIMENTAL
Intervention: Low hepcidin (>45.7 ng/mL) and low ferritin (>26 ng/mL)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: High hepcidin (>45.7 ng/mL) and low ferritin (>26 ng/mL)
Number of subjects: 148
Study: 23445876

Group type: EXPERIMENTAL
Intervention: Romiplostim to Eltrombopag
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Eltrombopag to Romiplostim
Number of subjects: 46

Group type: COMPARATOR
Intervention: Romiplostim
Number of subjects: 46

Group type: COMPARATOR
Intervention: Eltrombopag
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 46
Study: 23446180

Group type: EXPERIMENTAL
Intervention: Computer-delivered intervention to improve health literacy and HIV medication adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer-delivered intervention
Number of subjects: 0
Study: 23446828

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 734
Study: 23447001

Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and low-dose dexamethasone (CRd)
Number of subjects: 40
Study: 23447571

Group type: COMPARATOR
Intervention: Biventricular (BiV) pacing
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Multisite pacing using distal and proximal LV electrodes
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Multisite pacing configurations
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: All tested configurations of multisite pacing
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pacing from most distal and proximal electrodes
Number of subjects: 21
Study: 23448187

Group type: EXPERIMENTAL
Intervention: LAP sensor lead extraction using manual traction with a locking stylet and/or excimer laser sheath
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Manual traction alone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Excimer laser sheath (used in selected cases)
Number of subjects: 82
Study: 23448727

Group type: EXPERIMENTAL
Intervention: artesunate (0, 24, 48 hours)
Number of subjects: 215
Study: 23449267

Group type: EXPERIMENTAL
Intervention: Reversible diffusion hyperintensities (RDHs) observed in patients after stroke.
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Complete normalization of MR images.
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Characteristics of RDHs related to multiple infarct pattern.
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Characteristics of RDHs related to symptomatic carotid stenosis.
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: New additional lesions on follow-up DWI in patients with RDHs.
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Functional improvement on the National Institutes of Health Stroke Scale score.
Number of subjects: 153
Study: 23449428

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1809
Study: 23451835

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 30 mg daily for 4 weeks (NERD)
Number of subjects: 3313

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 60 mg daily for 8 weeks (EO)
Number of subjects: 3313

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily for 8 weeks (EO)
Number of subjects: 3313

Group type: COMPARATOR
Intervention: Placebo (NERD)
Number of subjects: 3313
Study: 23451840

Group type: EXPERIMENTAL
Intervention: Preventive measures for patients with increased familial risk of CRC
Number of subjects: 358

Group type: COMPARATOR
Intervention: Preventive measures for low-risk patients
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Genetic counselling for high-risk families
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Surveillance colonoscopy for moderate-risk families
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Knowledge of clinicians regarding familial risk and preventive measures
Number of subjects: 358
Study: 23451906

Group type: EXPERIMENTAL
Intervention: Combination of S100B and NSE levels with clinical parameters
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: S100B
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: NSE
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Neuromarker panel with high-risk factors (nausea, vomiting, amnesia, loss of consciousness)
Number of subjects: 107
Study: 23453092

Group type: EXPERIMENTAL
Intervention: Central adjudication of AMI
Number of subjects: 1096

Group type: COMPARATOR
Intervention: Local adjudication of AMI
Number of subjects: 1096
Study: 23453106

Group type: EXPERIMENTAL
Intervention: Roche hs-cTnT
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Beckman Coulter hs-cTnI
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Siemens hs-cTnI
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: hs-cTn changes in UA
Number of subjects: 842
Study: 23453513

Group type: EXPERIMENTAL
Intervention: Monthly intravitreal ranibizumab (0.3 mg or 0.5 mg)
Number of subjects: 1137

Group type: COMPARATOR
Intervention: Sham injections plus verteporfin photodynamic therapy (ANCHOR)
Number of subjects: 1137

Group type: COMPARATOR
Intervention: Sham injections alone (MARINA)
Number of subjects: 1137
Study: 23454241

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil with steroid withdrawal and reduced cyclosporine A (target level 50-90 ng/ml)
Number of subjects: 23
Study: 23454694

Group type: EXPERIMENTAL
Intervention: Intravenous fat (iv fat)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral fat (po fat)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous endotoxin (LPS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous glycerol
Number of subjects: 16
Study: 23456389

Group type: EXPERIMENTAL
Intervention: KRAS mutation
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: KRAS codon 13 mutations
Number of subjects: 148
Study: 23456563

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg plus FOLFOX6
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg plus reduced CapeOx (capecitabine 850 mg/m(2))
Number of subjects: 41
Study: 23456745

Group type: EXPERIMENTAL
Intervention: Ofatumumab (500 mg, 1000 mg)
Number of subjects: 6
Study: 23457002

Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 520
Study: 23457326

Group type: EXPERIMENTAL
Intervention: Peer support intervention (face-to-face or telephone) over 12 weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 9
Study: 23457331

Group type: EXPERIMENTAL
Intervention: Genetic prostate cancer risk assessment offered to patients requesting a PSA test in intervention group practices.
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Current guidelines for handling patients requesting a PSA test in control group practices.
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Patient experiences related to prostate cancer.
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Sociocultural aspects of genetic risk assessment.
Number of subjects: 1244
Study: 23457410

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 18
Study: 23457473

Group type: EXPERIMENTAL
Intervention: DNA prime/adenovirus boost malaria vaccine (3 monthly doses of DNA plasmids followed by a single boost with adenovirus vectors)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: DNA prime/adenovirus boost malaria vaccine
Number of subjects: 15
Study: 23458624

Group type: EXPERIMENTAL
Intervention: Gemcitabine and intravenous omega-3 rich lipid emulsion (n-3FA)
Number of subjects: 0
Study: 23459001

Group type: EXPERIMENTAL
Intervention: HHIP silencing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control lung tissues
Number of subjects: 0
Study: 23459494

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 18
Study: 23459496

Group type: EXPERIMENTAL
Intervention: Atazanavir-based therapy (including atazanavir, ritonavir, and emtricitabine-tenofovir)
Number of subjects: 35
Study: 23459515

Group type: EXPERIMENTAL
Intervention: NKG2D/NKp30-independent bispecific antibody construct (CD30xCD16A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 23459720

Group type: EXPERIMENTAL
Intervention: Standardized PCR assay with common calibrators and PCR master mix
Number of subjects: 40